Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
13.45
-0.27 (-1.97%)
At close: Mar 6, 2026, 4:00 PM EST
13.41
-0.04 (-0.30%)
After-hours: Mar 6, 2026, 7:53 PM EST
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $3.29M in the quarter ending September 30, 2025, with 16.58% growth. This brings the company's revenue in the last twelve months to $10.30M, down -8.79% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$10.30M
Revenue Growth
-8.79%
P/S Ratio
16.71
Revenue / Employee
$127,148
Employees
81
Market Cap
172.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 154.90M |
| Vaxart | 148.20M |
| Whitehawk Therapeutics | 14.38M |
| Caribou Biosciences | 11.16M |
| Cartesian Therapeutics | 1.09M |
| SAB Biotherapeutics | 114.70K |
TNXP News
- 3 days ago - Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development - GlobeNewsWire
- 5 days ago - Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - GlobeNewsWire
- 5 days ago - Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting - Benzinga
- 5 days ago - Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market - GlobeNewsWire
- 11 days ago - Tonix Pharmaceuticals to Participate in Two Investor Conferences in March - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewsWire